171 results about "Virulence factor" patented technology

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The invention discloses an ebbuselenium derivative, a pharmaceutical composition and application of the ebbuselenium derivative. The ebbeselenium derivative provided by the invention has the characteristic of inhibiting PPK activity, reduces the polyphosphoric acid (polyP) level of bacteria, reduces the formation of biological membranes, reduces the athletic ability of the bacteria, reduces the generation of virulence factors, can also enhance the sensitivity of the bacteria to antibiotics, and can be used for preparing a medicine for preventing and treating the diseases, such as the diseases, the pests and the like. Therefore, the compound is used for preventing and treating bacterial infection diseases.

The invention discloses a virulence factor gene relative abundance prediction model based on water quality physicochemical indexes, and relates to the technical field of ecological environment protection, and the virulence factor gene relative abundance prediction model comprises the following steps: taking a plurality of river water samples, obtaining virulence factor gene relative abundance of the river water samples, and obtaining water quality physicochemical index data of the river water samples; temperature, redox potential, ammonia nitrogen, nitrate nitrogen, nitrite nitrogen, total nitrogen, total dissolved solids, pH, conductivity, chlorophyll-a, chemical oxygen demand, dissolved oxygen, total organic carbon, total phosphorus, organic nitrogen, phosphate, carbon-nitrogen ratio and organic nitrogen / total nitrogen are taken as explanatory variables, and relative abundance of virulence factor genes is taken as a target variable. And establishing a regression model by adopting a GBM algorithm in an h2o packet in R software, and predicting the relative abundance of the virulence factor gene of the river water sample to be detected by utilizing the prediction model. The research provides a brand new method for predicting the relative abundance of the virulence factor gene and analyzing the environmental response of the virulence factor gene, and the method is suitable for identification and interpretation of a high-dimensional nonlinear ecosystem with complex interaction.

The invention provides functional identification and application of a novel cell virulence factor. Based on the research on the novel virulence factor of the cell, the invention also provides a polypeptide delivery system and application thereof. Wherein the polypeptide delivery system comprises a protein complex and a signal peptide, the signal peptide comprises at least 20 amino acids at the N-terminal of PagT1 protein or homologous protein thereof, and the signal peptide is used for guiding the polypeptide to be loaded into the protein complex and guiding the polypeptide to be positioned to the nucleus of eukaryotic cells. The research of the invention provides an important basis for constructing a safe and efficient novel tumor treatment system, and provides an innovative solution for treating serious diseases such as cancers.

The invention discloses application of fludarabine in treatment of methicillin-resistant staphylococcus aureus infection, and in an MRSA infected mouse model, it is verified that fludarabine can improve the survival rate of MRSA infected mice, reduce the MRSA bacterial count of lungs, livers, spleens and kidneys and relieve the injury degree of lungs, livers, spleens and kidneys caused by MRSA infection; pSMalpha3 is found to be an important virulence factor of MRSA, is closely related to high pathogenicity of MRSA, and can induce death of macrophages in a concentration-dependent manner, and fludarabine can significantly reduce cytotoxicity caused by PSMalpha3.

The invention belongs to the technical field of microorganisms, and discloses a bacteriophage which comprises a bacteriophage strain M01 with the preservation number of CCTCC M 20251724 or a variant strain of the bacteriophage strain M01. The variant strain and the bacteriophage strain M01 at least have 95% of average nucleotide identity on the genome. The bacteriophage M01 or the variant strain thereof provided by the invention has strong adsorption and lysis effects on aeromonas hydrophila, does not have genes for coding toxin, virulence factor or antibiotic resistance in a genome, and has good temperature stability and acid-base tolerance; the aeromonas hydrophila can be well applied to aquaculture to prevent and / or treat bacterial septicemia and other diseases caused by aeromonas hydrophila infection.

The present disclosure provides Pseudomonas aeruginosa (PA) neutralizing binding proteins or antibodies or derivatives thereof. The binding proteins of the present disclosure are specific for and bind to a wide range of epitopes present on the PA virulence factor, Pseudomonas aeruginosa V-antigen (PcrV) antigen. In an embodiment, the binding proteins or antibodies or derivatives thereof disclosed herein exhibit protective, neutralizing activity against P. aeruginosa. The binding proteins or antibodies or derivatives thereof disclosed herein have a high affinity to a wide range of PcrV epitopes. In an embodiment, the binding proteins disclosed herein are effective in limiting a PA infection.

The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and / or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.

The invention provides a lactobacillus plantarum 18 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No.31277. The lactobacillus plantarum 18 has the advantages that the lactobacillus plantarum 18 is prepared from lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum and lactobacillus plantarum; the plant lactobacillus 18 can inhibit growth of propionibacterium acnes, inhibit expression of virulence factors (biological membranes, lipase and the like) of the propionibacterium acnes, relieve inflammation, inhibit autophagy of cells, scavenge free radicals and inhibit activity of tyrosinase, so that the plant lactobacillus 18 has the effects of resisting acnes, dermatitis and oxidation and whitening skin. The plant lactobacillus 18 or the metabolite of the plant lactobacillus 18 can be used for preparing products with the effects or effects.

The invention discloses an application of a compound 5928-0054 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 5928-0054 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protection effect on mice infected by MRSA staphylococcus aureus USA300, and has the application of preparing the anti-staphylococcus aureus hemolysin medicine and the medicine for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 5928-0054 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 5928-0054 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.

The invention discloses a novel aeromonas salmonicida virulence comparison method based on image analysis, and the method comprises the steps: obtaining aeromonas salmonicida samples from different sources, carrying out image collection, and obtaining the image data of aeromonas salmonicida; carrying out preprocessing and Canny edge detection on the collected image data, segmenting a microorganism image, and extracting a target microorganism region; extracting characteristics related to the toxicity of aeromonas salmonicida from the segmented image through an image analysis technology; the extracted features are compared with a known aeromonas salmonicida virulence factor database, and the virulence strength of the thalli to be detected is evaluated; and arranging and summarizing data generated in a comparison process, and outputting a comparison and evaluation result in a visual form. According to the method disclosed by the invention, the virulence characteristics of aeromonas salmonicida from different sources or under different conditions can be quickly and accurately compared, and the difference between strains can be more intuitively reflected, so that the accuracy and efficiency of virulence comparison are improved.

The present application relates to the field of medicine, and particularly relates to a kind of uracil compound containing formula (I) and its application in preparing bacterial virulence factor lasB inhibitor.The uracil compound involved in the present application is verified by in vitro drug efficacy, and most of the obtained compounds have excellent lasB inhibitory activity, can be used for preparing anti-toxicity agent, and has the potential to be developed as a new antibacterial drug.

The invention belongs to the technical field of biological medicine, and particularly relates to application of 4-imidazole formaldehyde in a pseudomonas aeruginosa quorum sensing inhibitor. It is found for the first time that 4-imidazole formaldehyde can inhibit quorum sensing of pseudomonas aeruginosa, reduce QS system regulation gene expression and virulence factor yield and remarkably reduce infection caused by QS system regulation gene expression and virulence factor yield; the drug application designed on the basis of bacterial metabolism can avoid the drug resistance of a conventional bacteriostatic agent, and a new strategy is provided for prevention and treatment of pseudomonas aeruginosa infection.

The invention relates to the technical field of biology, in particular to a helicobacter pylori antibody typing reagent combination as well as a preparation method and application of the helicobacter pylori antibody typing reagent combination. Comprising an acridinium ester mouse anti-human IgG complex solution, a biotin-Ure recombinant protein complex solution, a biotin-CVfp fusion protein complex solution and a streptavidin magnetic bead mother solution. The biotin-Ure recombinant protein complex liquid is obtained by labeling Ure recombinant protein with biotin, and the amino acid sequence of the Ure recombinant protein is as shown in SEQ ID No. 1; the biotin-CVfp fusion protein complex liquid is obtained by labeling CVfp fusion protein with biotin, the CVfp fusion protein carries out fusion expression on antigen epitopes of CagA and VacA, and the amino acid sequence of the CVfp fusion protein is shown as SEQ ID No.2. The problems that at present, Hp virulence factor typing detection indexes are complex, reagent cost is high, and detection flux is low are solved.

The invention relates to the technical field of microbial technology and disease control, and discloses an ETEC phage and a preparation method thereof, the preservation number of the ETEC phage CQ615 is CGMCC No.46362, and the preservation time is December 30, 2024. According to the scheme, the bacteriophage CQ615 which is separated and purified in sewage by taking ETEC as host bacteria can be used for simultaneously splitting multiple serotypes of escherichia coli and has a relatively wide splitting spectrum; whole genome sequencing is carried out by extracting nucleic acid of the bacteriophage, and data are analyzed to find that the bacteriophage is free of non-virulence factors and drug-resistant factors and can become a potential selection mode for safe prevention and treatment of Escherichia coli; through verification of in-vivo and in-vitro experiments, the bacteriophage CQ615 can effectively reduce the number of ETEC bacteria in milk and lettuce, and can improve the survival rate of greater wax moths infected by ETEC in greater wax moth in-vivo experiments.

Provided herein are vaccine compositions for preventing and combating infection by Shigella. In particular, the present disclosure provides a composition comprising a Shigella virulence factor VirG (or IcsA) protein or a fragment thereof comprising about 100-400 amino acids of the VirG protein having an amino acid sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 2.

The invention discloses application of lvpA-NF-kappa B p65 interaction in pathogenicity evaluation of staphylococcus lugdungensis. The invention reveals that a staphylococcus lugdungensis virulence factor lvpA can be directly and specifically combined with a key protein p65 of a host NF-kappa B signal channel for the first time. The invention provides an in-vitro detection kit for a non-diagnostic purpose. The in-vitro detection kit comprises a reagent capable of capturing or marking lvpA protein and p65 protein. Meanwhile, the invention discloses application of the lvpA protein or the functional fragment of the lvpA protein in preparation of a reagent or a kit for evaluating potential pathogenicity of a strain in vitro or screening candidate substances interfering the interaction, and application of polypeptide capable of competitively inhibiting the interaction in preparation of an in-vitro reagent. The invention provides a new perspective for the research on the pathogenic mechanism of staphylococcus lugdunensis infection, and provides a new target spot and means for developing related detection tools and anti-toxicity strategies.

The invention relates to application of raloxifene hydrochloride in preparation of a population effect inhibitor. The invention verifies that the raloxifene hydrochloride can inhibit the population effect of bacteria through a violaceum violaceum luminescence method, and further proves that the raloxifene hydrochloride can inhibit the population effect of pseudomonas aeruginosa and the generation of virulence factors through the inhibition of biological back membrane formation and the inhibition effect of virulence factor generation. The compound is expected to be developed into a clinically available group effect inhibitor, and has an important research value for solving the problems of bacterial infection and drug resistance.

The present application belongs to the technical field of quorum quenching enzyme preparation, and particularly relates to a multi-target quorum quenching enzyme preparation and a preparation method and application thereof, such as being mainly used for inhibiting the virulence factors of Pseudomonas aeruginosa, and including acyl homoserine lactone acyltransferase AiiO protein and 3-hydroxy-4-oxoquinolone 2,4-dioxygenase AqdC protein, and the mass ratio of the two is 20:(1-25); such as being mainly used for inhibiting the virulence factors and the synthesis of biological membranes of Pseudomonas aeruginosa, and further including deferiprone, and the mass ratio of AiiO, AqdC and deferiprone is 20:(1-25):(0.695-2.78), the present application can target the Las, Rhl and PQS of Pseudomonas aeruginosa, the yield and stability of the prepared AqdC protein are both high, the two types of enzymes are used in combination after the regulation amount, and the virulence factors regulated by different quorum sensing pathways in Pseudomonas aeruginosa are effectively inhibited; the regulation amount of deferiprone is used in combination with the two types of quorum quenching enzymes, and the virulence and biological membranes of Pseudomonas aeruginosa can be effectively inhibited in a comprehensive manner.

The application provides a hot liquid source quorum quenching strain Shiquan Haeyuan bacteria and application thereof, the strain screened can inhibit pathogenic bacteria and is used for preparing bacteriostatic drugs; the preservation number of the Shiquan Haeyuan bacteria screened is CCTCC NO: M 20251224.The application also provides an AHL degradation enzyme Aii937 protein separated from the YESM3 strain, characterized in that the amino acid sequence of the protein is SEQ ID NO: 2.The YESM3 strain of the application can block the QS path of pathogenic bacteria through AHL lactonase Aii937, reduce the secretion of virulence factors of pathogenic bacteria; the strain YESM3 has no pathogenicity.AHL lactonase does not have broad spectrum, has strong substrate specificity, and only degrades C6-HSL and 3OC-C 14 -HSL.

The present invention discloses the application of the LI0004 protein target in the preparation of a drug for inhibiting the proliferation of Lawsonia infection cells, belonging to the field of biomedicine. IPEC-J2 cells were used to construct an in vitro Lawsonia infection model, and the mechanism of action of the LI0004 protein as a virulence factor in Lawsonia infection cells was studied. The relationship between the LI0004 protein in regulating the activation of the cell cycle signaling pathway and the toxic mechanism was elucidated. The results showed that the LI0004 protein directly bound to the Notch 1 protein, activated the Notch 1 signaling pathway, and then promoted the proliferation of IPEC-J2 cells. The present invention also constructed a mouse model infected with the LI0004 protein. The results showed that the LI0004 protein can produce pathological changes similar to Lawsonia infection in vivo, and the Notch 1 signaling pathway is an important mechanism for the intestinal cell proliferation caused by it.

The invention relates to a temperature-sensitive gel based on EGCG and quercetin compounding and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The temperature-sensitive gel is prepared from the following components in parts by mass: 5 parts of EGCG (epigallocatechin gallate), 5 parts of quercetin, 35 to 40 parts of liquid grease, 30 parts of soybean phospholipid, 4 to 5 parts of phytantriol, 4 parts of Tween, 10 to 14 parts of organic solvent and 2 parts of peppermint oil. The EGCG and the quercetin are combined to play an antifungal role by destroying fungal cell membranes and inhibiting virulence factors (such as hypha formation), and the quercetin blocks fungal cell wall synthesis by inhibiting beta-1, 3-glucan synthetase, so that the combined synergistic potential of the EGCG and the quercetin not only improves the biocompatibility of the gel preparation, but also improves the bioavailability of the gel preparation. And the specific design aiming at a fungal biological membrane is met.

The invention relates to the technical field of probiotics, in particular to swine-derived probiotic escherichia coli CP57 (Escherichia coli CP57) as well as a preparation method and application of the swine-derived probiotic escherichia coli CP57. The strain is separated from feces of healthy piglets, has good acid resistance and cholate resistance, does not carry virulence factors of common diarrhetic escherichia coli, does not have obvious cytotoxicity and has good safety. The strain can significantly inhibit the growth of salmonella, can relieve clinical symptoms caused by salmonella infection in a salmonella infected mouse model, and reduces the content of salmonella in mouse feces and in vivo. The Escherichia coli CP57 provided by the invention has the potential of preventing and controlling enteropathogenic bacteria infection of livestock, can be used for preparing a microecological preparation for preventing and controlling intestinal infection of livestock, and has important application value.

This invention discloses the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa infection. This invention provides the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa (… Pseudomonas aeruginosa Application in infectious agents. The 6-methyladenine described in this invention inhibits the quorum sensing of Pseudomonas aeruginosa and the production of related virulence factors, thereby suppressing Pseudomonas aeruginosa infection in vivo and in vitro, reducing host mortality, and providing a new therapeutic strategy for the prevention and control of Pseudomonas aeruginosa infection.

The present invention relates to compounds of formula (I) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB.These compounds are useful in the treatment of bacterial infections, especially caused by P. aeruginosa.

The invention relates to the technical field of biology, in particular to bordetella bronchiseptica BAH01 and application thereof. The invention provides an I-phase strain, namely bordetella bronchiseptica BAH01, which is high in virulence and contains seven virulence factors. At present, a strain vaccine which simultaneously meets the two conditions is not found. The strain has the following advantages: (1) a biological product prepared from an inactivated vaccine prepared from bordetella bronchiseptica BAH01 is extremely high in immune efficacy; (2) the Bordetella bronchiseptica BAH01 is high in proliferation titer on a Ginger Boehmek culture medium; (3) the bordetella bronchiseptica provided by the invention has strong pathogenicity to mice; and (4) the inactivated product of Bordetella bronchiseptica BAH01 provided by the invention has good immunogenicity, can completely block the attack of Bordetella bronchiseptica on mice, can provide higher immune protection rate, and has basic potential for developing vaccines.

The invention relates to an application of pimozide in preparation of a population effect inhibitor. The invention verifies that pimozide can inhibit the population effect of bacteria through a violaceum violaceum luminescence method, and further proves that pimozide can inhibit the population effect of pseudomonas aeruginosa and the generation of virulence factors through the inhibition of biological back membrane formation and the inhibition effect of virulence factor generation. The compound is expected to be developed into a clinically available group effect inhibitor, and has an important research value for solving the problems of bacterial infection and drug resistance.

The application discloses an ebselen derivative, a pharmaceutical composition and application thereof. The ebselen derivative has a structure as shown in formula (I) or formula (II). The ebselen derivative provided by the application has the characteristics of inhibiting PPK activity, reducing the polyP level of bacteria, reducing the formation of a biofilm, reducing the movement ability of bacteria, reducing the generation of a virulence factor, and enhancing the sensitivity of bacteria to antibiotics, and thus can be used for preventing and treating bacterial infectious diseases.

The present application relates to the technical field of biology, and particularly relates to a bacteriophage vB_SalP_SE29, a bacteriophage vB_SalP_SE29 preparation and application thereof.The present application provides the bacteriophage vB_SalP_SE29, and the preservation number of the bacteriophage vB_SalP_SE29 is CGMCC No.46499.The present application provides a chicken salmonella pullorum bacteriophage, and through whole genome sequencing analysis, no gene sequence related to lysogeny conversion, antibiotic resistance and virulence factor is detected in the genome of the bacteriophage, so that the biological safety of the bacteriophage for drug development and bactericidal product research is ensured from a molecular level, and potential biological risks are effectively avoided.